@article{oai:nagoya.repo.nii.ac.jp:02001431, author = {Nishida, Tetsuya and Kobayashi, Takeshi and Sawa, Masashi and Masuda, Shinichi and Shibasaki, Yasuhiko and Goto, Tatsunori and Fukuhara, Noriko and Fujii, Nobuharu and Ikegame, Kazuhiro and Sugita, Junichi and Ikeda, Takashi and Kuwatsuka, Yachiyo and Suzuki, Ritsuro and Najima, Yuho and Doki, Noriko and Kato, Tomonori and Inagaki, Yuichiro and Utsu, Yoshikazu and Aotsuka, Nobuyuki and Masuko, Masayoshi and Terakura, Seitaro and Onishi, Yasushi and Maeda, Yoshinobu and Okada, Masaya and Teshima, Takanori and Murata, Makoto}, issue = {3}, journal = {Annals of Hematology}, month = {Mar}, note = {To overcome the delayed or failed engraftment after unrelated cord blood transplantation (CBT), we conducted a multicenter phase II study of intrabone single-unit CBT without antithymocyte globulin (ATG) for adult patients with hematological malignancies (UMIN-CTR, UMIN000020997). Sixty-four patients received an intrabone injection of unwashed (n = 61) or washed (n = 3) cord blood after local anesthesia. All injection-related adverse events were mild and resolved spontaneously. Sixty-two patients were evaluable for the efficacy of intrabone CBT of serological HLA-A, -B, and -DR ≥ 4/6 matched cord blood with a median number of 2.57 × 10^7/kg cryopreserved total nucleated cells. The probability of survival with neutrophil engraftment on day 28 was 77.4% (95% confidence interval, 67.0–85.8%), which exceeded the threshold value. The cumulative incidences of neutrophils ≥ 0.5 × 10^9/L on day 60 was 80.6% (68.2–88.6%), with a median time to recovery of 21 days after transplantation. The cumulative incidences of platelets ≥ 20 × 10^9/L and platelets ≥ 50 × 10^9/L on day 100 were 75.8% (62.6–84.9%) and 72.6% (59.4–82.1%), respectively, with median time to platelets ≥ 20 × 10^9/L and platelets ≥ 50 × 10^9/L of 38 and 45 days after transplantation, respectively. The cumulative incidences of grade II–IV and III–IV acute graft-versus-host disease were 29.0% and 6.5%, respectively. All responded to steroid therapy, and secondary treatments were not required. The present study suggests the efficacy of intrabone single-unit CBT without ATG in terms of early engraftment and controllable acute graft-versus-host disease.}, pages = {743--752}, title = {A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin}, volume = {100}, year = {2021} }